Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Ramaswamy Govindan, MD, and Yi-Long Wu, MD: Results From the CTONG ADJUVANT Trial

Posted: Monday, June 5, 2017

Ramaswamy Govindan, MD, of Washington University, and Yi-Long Wu, MD, of the Guangdong Lung Cancer Institute, discuss phase III study findings on gefitinib vs vinorelbine plus cisplatin as adjuvant treatment in stage II-IIIA (N1-N2) non–small-cell lung cancer with EGFR-activating mutation.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.